Synthesis and cytotoxic activity of (2-arylquinazolin-4-yl)hydrazones of 2-hydroxybenzaldehydes

2-Phenyl-6,7-difluoro and 2-(4-fluorophenyl)quinazoline derivatives bearing salicylidenhydrazino fragments at position 4 were prepared based on 4,5-difluoroantranilic acid or anthranilamide. Molecular docking to casein kinase 2 was performed; compounds with high in silico activity to CK2 were revealed. Cytotoxic activity of the synthesized compounds was studied on cancer cell line MDA-MB-231 and normal cell line WI26 VA4

Triazavirin—A Novel Effective Antiviral Drug

This review outlines the data of numerous studies relating to the broad-spectrum antiviral drug Triazavirin that was launched on the Russian pharmaceutical market in 2014 as an anti-influenza drug (the international non-patented name is Riamilovir). The range of antiviral activity of Triazavirin has been significantly expanded during recent years; in particular, it has been shown that Triazavirin exhibits activity against tick-borne encephalitis, Rift Valley fever, West Nile fever, and other infections of viral etiology. This drug has been approved for treatment of influenza and acute respiratory infections by the Russian Ministry of Health on the basis of comprehensive clinical trials involving over 450 patients. Triazavirin was found to be a highly effective and well-tolerated drug, allowing its over-the-counter sale. The recently published data on the use of Triazavirin in clinical practice for the treatment of patients with COVID-19 are discussed, with special attention paid to potential biological targets for this drug